Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-up

Catherine Thieblemont

February 16, 2024


Presentations

TCR and inhibitory receptor genome editing for hematological and solid tumors - Fabio Ciceri

Featured presentations